A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Renal Cell Carcinoma Clinical Trial

Official title:

Registry-based Non-interventional Analysis of Advanced/Metastatic Renal Carcinoma Treatment Patterns and Outcomes in the Hospital District of Southwest Finland.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05363072
• Other study ID #: A4061098
• Secondary ID: FIN-RCC-RWD
• Status: Completed
• Start date: June 1, 2022
• Est. completion date: September 30, 2022

Study information

• Verified date: April 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 191
• Est. completion date: September 30, 2022
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

For the characteristic group:

• Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision [ICD]-10:64) during 01 January 2010 and 31 December 2021

For the mRCC group:

• ICD-10 diagnosis code for metastasis (C77*-C79*), or

• American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients

• Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease

• Initiation of treatment for mRCC

Exclusion Criteria:

For the characteristic group:

• Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)

• Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021

For the mRCC group:

• Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010)

• Patients without treatment for mRCC

Related Conditions & MeSH terms

• Cancer of Kidney
• Cancer of the Kidney
• Carcinoma
• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms
• Renal Cancer
• Renal Cell Cancer
• Renal Cell Carcinoma

Locations

Country	Name	City	State
Finland	Pfizer Finland	Helsinki

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demographical Characteristics of Participants (treated)		During post-index period (January 2010 - December 2021)
Primary	Demographical Characteristics of Participants (non-treated)		During post-index period (January 2010 - December 2021)
Primary	International Metastatic Database Consortium (IMDC) Risk Group Status at Initiation of Treatment (treated)		During post-index period (January 2010 - December 2021)
Primary	IMDC Risk Group Status at Initiation of Treatment (non-treated)		During post-index period (January 2010 - December 2021)
Primary	Number of Treatments Received in the Advanced/Metastatic Renal Cell Carcinoma (mRCC) Setting		During post-index period (January 2010 - December 2021)
Primary	Number of Treatment Sequences Received in the mRCC Setting		During post-index period (January 2010 - December 2021)
Primary	Time to next treatment (TTNT)		During post-index period (January 2010 - December 2021)
Primary	Overall Survival (OS)		During post-index period (January 2010 - December 2021)
Secondary	Number of Participants With Morbidities with Metastatic RCC		During post-index period (January 2010 - December 2021)
Secondary	Healthcare Resource Utilization		During post-index period (January 2010 - December 2021)

External Links

•   To obtain contact information for a study center near you, click here.